Validation of Biomarkers of the Tumor Microenvironment
Technical Report,30 Sep 2014,29 Sep 2015
University of California Irvine United States
Pagination or Media Count:
Currently the diagnosis of prostate cancer rests on the results of a biopsy. There are over one million biopsies performed in the U.S. alone every year. Most, about 63, are negative. Several large series have revealed that 30-40 of these miss tumors in spite of taking 12 or more cores under ultrasound guidance. Patients recommended for repeat biopsy usually in 3-12 months receive no treatment while tumor may progress. However all biopsies contain ample stroma. Others and we have observed hundreds of gene activity changes in stroma near tumor. We have developed and published a general classifier for the diagnosis of prostate cancer based on an RNA profile of 131 genes derived from analysis of frozen prostatectomy and normal stroma samples. It has been tested on 364 independent cases and shown to be 97 accurate. Preliminary studies indicate that equivalent performance may be obtained from approximately 45-65 genes with the highest differential expression.